Importantly, in our study, no neprilysin activation was detected in the heart after treatment with SST-scFv8D3 (Figure 5J), which can have the potential in reducing the risk of severe adverse events such as the risk for heart failure, that today is often treated with neprilysin inhibitors 77. This evidence concerns the gene MME and heart failure.